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Purpose: The chick chorioallantoic membrane (CAM) assay can provide an alternative
versatile, cost-effective, and ethically less controversial in vivo model for reliable screening
of drugs. In the presented work, we demonstrate that CAM assay (in ovo and ex ovo) can
be simply employed to delineate the effects of cisplatin (CDDP) and ellipticine (Elli) on
neuroblastoma (Nbl) cells in terms of their growth and metastatic potential.
Methods: The Nbl UKF-NB-4 cell line was established from recurrent bone marrow
metastases of high-risk Nbl (stage IV, MYCN amplification, 7q21 gain). Ex ovo and in ovo
CAM assays were optimized to evaluate the antimetastatic activity of CDDP and Elli.
Immunohistochemistry, qRT-PCR, and DNA isolation were performed.
Results: Ex ovo CAM assay was employed to study whether CDDP and Elli exhibit any
inhibitory effects on growth of Nbl xenograft in ex ovo CAM assay. Under the optimal
conditions, Elli and CDDP exhibited significant inhibition of the size of the primary tumor.
To study the efficiency of CDDP and Elli to inhibit primary Nbl tumor growth, intravasation,
and extravasation in the organs, we adapted the in ovo CAM assay protocol. In in ovo
CAM assay, both studied compounds (CDDP and Elli) exhibited significant (p < 0.001)
inhibitory activity against extravasation to all investigated organs including distal CAM.
Conclusions: Taken together, CAM assay could be a helpful and highly efficient in vivo
approach for high-throughput screening of libraries of compounds with expected
anticancer activities.
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Neuroblastoma (Nbl) is a heterogeneous pediatric cancer derived
from the sympathetic nervous system arising from the neural
crest (1). It is manifested as a solid malignant tumor residing
around the spinal cord in the pelvis, chest, or neck and in the
abdomen. Based on the statistics, Nbl accounts for ~15% of
pediatric cancer deaths (2). While low- and intermediate-risk
forms of Nbl are curable, patients with high-risk diseases have a
3-year event-free survival rate of only ~20% (3, 4), highlighting
the utmost need for novel more efficient therapeutic agents.
Preclinical trials of novel anticancer therapeutic modalities
require comprehensive in vitro and in vivo investigation. At the
in vivo level, mouse xenograft models are the most common
models employed to assess the drugs’ behavior (5). Noteworthy,
rodent preclinical models are expensive and time-consuming
and provoke ethical concerns. In contrast, the chick
chorioallantoic membrane (CAM) assay is an efficient
alternative to commonly used animal models (6, 7). Chick
embryo is characterized by its essential immunodeficiency
during its embryonic life, which is not typical for mice that
frequently do not allow induction and growth of all types of
human cancers (8). The CAM assay is a well-established in vivo
system to study the angiogenesis and the carcinogenesis of
various tumors, including prostate cancer (9), glioblastoma
(10), osteosarcoma (11), colon cancer (12), non-small cell
lung cancer (13), thyroid cancer (14), or Nbl (15). For these
purposes, both in ovo (16) and ex ovo (17) CAM assays have
been employed for various purposes varying in experiments
from protocol to protocol. The benefit of the ex ovo CAM assay
is that it enables a straightforward observation of angiogenesis,
which is of utmost interest not only for microvascular research
but also for screening of antiangiogenic drugs. On the other
hand, in ovo CAM assay allows us easy monitoring of tumor
extravasation and intravasation into the microvasculature and
consequent formation of metastases in organs. Nevertheless,
standardization of such protocols shows the main challenges
and potential bottlenecks could be helpful to stimulate wider
usage of CAM.
Herein, we provide a description and a detailed pipeline of
development of both in ovo and ex ovo CAMmodels xenografted
with human Nbl cells (Figure 1). The reported approach allows
for a reliable production of 3-D, vascularized tumors
histologically resembling undifferentiated Nbl. Importantly, we
demonstrate that CAM is not only an in vivo model for
investigation of angiogenesis and carcinogenesis, but also, as
evidenced on the case study of conventional [cisplatin (CDDP)]
and experimental [ellipticine (Elli)] cytostatics, it is an efficient
model to study the activity of anticancer compounds. Without
any doubt, the pipelined protocol can be thus utilized for high-
throughput in vivo screening of candidate compounds to reveal
the promising anticancer substances in a cost- and time-effective
manner. Noteworthy, the use of CAM assay provides an efficient
way to reduce and/or replace experiments on animals and could
therefore accelerate development and preclinical testing of novel
and more efficient therapeutic modalities, which could be
interesting for various types of pathologies.Frontiers in Oncology | www.frontiersin.org 2MATERIALS AND METHODS
Chemicals
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO,
USA). The buffers and solutions were prepared with ACS purity
chemicals unless noted otherwise.
Cell Line and Culturing
The Nbl UKF-NB-4 cells were a generous gift from Prof. Tomas
Eckschlager (Department of Pediatric Hematology and
Oncology, 2nd Faculty of Medicine, Charles University in
Prague and Motol University Hospital, Prague, Czechia). UKF-
NB-4 cells were established from recurrent bone marrow
metastases of high-risk Nbl (stage IV, MYCN amplification,
7q21 gain). The cells were cultured in Iscove’s modified
Dulbecco’s medium (IMDM) with 10% fetal bovine serum and
grown at 37°C and 5% CO2. The cells were passaged at regular
intervals twice a week.
Ex Ovo Chorioallantoic Membrane Assay
The fertilized chicken eggs purchased from a local provider
(Vykrm Trebic, Trebic, Czechia) were incubated lying
horizontally with intermittent rotation at 37.5°C and 65%
humidity for 3 days. Then, the eggshells were cracked, and
embryos were transferred into small, sterile plastic bowls
(VWR, Radnor, PA, USA). During the transfer process, viability
of the embryos was monitored, and the developing embryo must
be always placed on the top of the yolk sac. Then, the bowls were
covered using Petri dishes and incubated for 7 days more after
which embryos were xenografted (four to six different sites that
were always near to small vessels) with 5 × 104 cells/25 µl of
serum-free medium always close to small vessels, and the site of
inoculation was labeled on a Petri dish. The embryos’ survival
rates were checked on a daily basis. Before xenografting, UKF-
NB-4 cells were pre-labeled with CellTracker Green (Invitrogen,
Carlsbad, CA, USA), mixed with Geltrex LDEV-Free reduced
growth factor basement membrane matrix (Invitrogen, Carlsbad,
CA, USA), and implanted on the CAM at an initial seeding
density of ~5 × 104. After 3 days of incubation, 5 µl of 100 mM
CDDP or 200 mM Elli in phosphate-buffered saline (PBS) was
administered directly onto each microtumor, and the embryos
were left without movement for 30 min to enable absorption of
CDDP/Elli to the microtumor and to avoid possible runoff from
the microtumor sites. Then, ex ovo cultures were further
incubated at 37.5°C for 24 h. For the purpose of fluorescence
angiography, vascular endothelium was labeled with rhodamine-
labeled Lens culinaris agglutinin (LCA; 50 ml of 5 mg/ml) (Vector
Laboratories, Burlingame, CA, USA) administered in peripheral
vein with 30-gauge hypodermic needle. Upon this procedure, the
embryos were further incubated (3 min) to enable LCA to
circulate and stain vascular endothelium. Then, by cutting the
vitelline arteries, the embryos were sacrificed. CAM sites that
produced microtumors were extracted with a 1-cm margin
around microtumors and fixed using 3.7% paraformaldehyde in
PBS. For subsequent fluorescence angiography, the confocal laser
scanning microscopy (CLSM) (LSM 880, Carl Zeiss, Jena,
Germany) was used with the emitted light from rhodamineSeptember 2021 | Volume 11 | Article 707366
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from UKF-NB-4 cells was labeled with CellTracker Green
collected at 515–525 nm.
In Ovo Chorioallantoic Membrane Assay
In ovo CAM assay to determine the antimetastatic activity of
CDDP and Elli followed the protocol described by Crespo et al.
(18). Briefly, fertilized chicken eggs were incubated with
intermittent rotation (37.5°C, 65% humidity, 10 days). On day
10, eggs were put on a rack; and a hole was drilled in the air sac at
the blunt end of the egg using a 30-gauge syringe. Further, a
Dremel rotary tool kit (Dremel, Racine, WI, USA) was employed
to drill another hole near the allantoic vein while using a light
source to control the drilling and to avoid causing an injury to
the CAM. After that, another hole was drilled with a 20-gauge
syringe needle and a mild vacuum was applied to the air sac hole
using an automated pipette with a Tygon tube to drop the CAM
from the shell. Further, a square window (~1 cm2) was drilled
with a cut-off wheel (Dremel) close to the bifurcation of the
allantoid vein. Then, 25 µl of the suspension of ~1 × 106 UKF-
NB-4 cells in the serum-free medium was applied close to the
allantoid vein bifurcation using a pipette while avoiding a direct
contact with the CAM. After xenografting, the eggs were left
standing upright for 5–10 min in order to allow the cells to settle,Frontiers in Oncology | www.frontiersin.org 3sealed with tape, and left to grow (6 days at 37.5°C) on a
stationary incubator. Then, 100 µM of CDDP or 200 µM of
Elli in PBS was added topically directly onto each microtumor on
the upper CAM and the eggs were left without movement for 30
min to enable absorption of CDDP/Elli to the microtumor and to
avoid possible runoff from the microtumor sites. After that, the
eggs were incubated for additional 24 h according to our
previous study (15). At defined time-points, parts of the CAM,
liver, lung, and brain were extracted to carry out additional
analyses and to quantify the amount of human tumor cells that
accumulated in the tissues using qPCR. In the European Union
countries, CAM assay is not considered an animal experiment
and, therefore, does not require ethical approval.
Isolation of DNA and qRT-PCR
Genomic DNA from tissues was extracted using DNeasy Blood &
Tissue kit (Qiagen, Germantown, MD, USA). Before qPCR, the
DNA was diluted 1:50 or 1:25 to get 30 ng/µl in nuclease-free
water. To quantify human tumor cell DNA in the extracted
tissues, we employed qPCR quantifying human Alu sequences by
utilizing Alu-specific primers and SYBR green mix amplification
kit. Reaction mix was prepared with 0.4 mM of each primer in a
final volume of 10 ml. Chicken GAPDH primers were utilized as
internal control. The qPCR conditions were as follows: 95°C forFIGURE 1 | Workflow of ex ovo and in ovo chick chorioallantoic membrane (CAM) assays for development of neuroblastoma (Nbl) xenograft using UKF-NB-4 cells.
For ex ovo CAM assay, the fertilized eggs were incubated for 3 days. Then, the eggshell was cracked, and the content was transferred into sterile dishes followed by
incubation (additional 6 days). Nbl cells were then grafted on the CAM (specifically on vascular branches), and the embryos were incubated (additional 4 days). CAM
areas with microtumors were extracted, keeping a 1-cm margin of healthy tissue, and were fixed. For in ovo CAM assay, the fertilized eggs were incubated for 10
days. In the eggshell, a window was opened, and Nbl cells were xenografted. The eggs were incubated for additional 6 days.September 2021 | Volume 11 | Article 707366
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From the UKF-NB-4 cell DNA, standard curve was generated
using a dilution series (102, 103, and 104). The standard curve was
subsequently utilized to quantify human tumor cells in chick
tissues through Ct values obtained in triplicates. To statistically
evaluate results, Student’s t-test or ANOVA was carried out in
GraphPad Prism (GraphPad, San Diego, CA, USA).
The specificity of the qPCR reactions was verified by melting
curve analysis. Primer design was done using the genes sequences
available at the NCBI GenBank (www.ncbi.nih.gov).
The following primers were custom designed and synthesized by
Sigma-Aldrich: Alu(human)Fw: 5 ′-ACGCCTGTAAT
CCCAGGACTT-3′ Alu(human)Rv: 5′-TCGCCCAGGCTGGC
T G G G T G C A - 3 ′ ; G A P D H ( c h i c k e n ) F w : 5 ′ -
GAGGAAAGGTCGCCTGGTGGATCG-3′ and GAPDH
(chicken)Rv: 5′ GGTGAGGACAAGCAGTGAGGAACG 3′.
Immunohistochemistry
After extraction, tissues were embedded in paraffin and cut using
microtome; and 5-µm sections were placed on poly-L-lysine-
treated slides. Before staining, slides were deparaffinized, and
tissues were rehydrated. After that, slides were dried (1 h at 60°C
or overnight at 37°C). Then, permeabilization of cells was carried
out by incubation (10 min) of tissues with 0.1% IGEPAL in 1×
Tris Buffered Saline (TBS). After that, the specimens were
washed (2×, 5 min with 1× TBS), and non-specific bindings
were blocked using a serum-free blocking agent, background
punisher (BIOCARE Medical, Pacheco, CA, USA), for 8 min.
Then, 1% bovine serum albumin (BSA) 0.05% IGEPAL in 1×
TBS solution with a primary mouse anti-rat CD44 antibody
(diluted 1:100) (Antibodies Online, Aachen, Germany) or
without primary antibody (negative control) was incubated
overnight (4°C). After incubation, specimens were washed in
1× TBS and incubated with 3× hydrogen peroxide in 1× TBS for
20 min to quench endogenous peroxidase. After that, the slides
were washed again using 1× TBS and incubated (1 h) with a
secondary anti-mouse biotinylated antibody (Vector
Laboratories, Burlingame, CA, USA) (dilution 1:400 in 1% BSA
0.05% IGEPAL in 1× TBS). Then, slides were washed, as
described above, and tissues were incubated (30 min) with
horseradish peroxidase avidin D (dilution 1:500 in 1× TBS).
Finally, slides were washed again and incubated (5 min) with
diaminobenzidine (Gibco, Gaithersburg, MD, USA). In addition,
tissues were stained with hematoxylin, dehydrated, cleared, and
mounted with DPX mountant. Micrographs were captured by
Zeiss Axio Scope A1 microscope (Carl Zeiss).RESULTS
Ex Ovo Chorioallantoic Membrane Assay
Examining the Effect of Cisplatin
and Ellipticine
In this study, we adapted the conditions of ex ovo CAM
previously reported by Herrero et al. (19) and Casar et al. (20).
Use of this methodology allows the survival of embryos toFrontiers in Oncology | www.frontiersin.org 4be >50%. Established ex ovo CAM assay was further employed
to study whether CDDP and Elli exhibit any inhibitory effects on
growth of Nbl xenograft in ex ovo CAM assay. Figure 2 shows that
on embryonic development day 3, embryo was transferred
successfully with an intact egg yolk (Figure 2A1), and live
embryo was on embryonic development from day 3 to 10
(Figures 2A2–A4). At day 10 of embryonic development, Nbl
cells were xenografted on the CAM and the sites of inoculation
were labeled on Petri dish covering the bowl with ex ovo-incubated
embryo (Figure 2A4). At day 14, the Nbl cells forming
microtumors were harvested (Figure 2A5), and the whole CAM
was processed for subsequent analyses (Figure 2A6).
Figures 2B.1, B.2 demonstrate that UKF-NB-4 xenografts
were established correctly on CAM as evidenced by extensive
green signal of CellTracker-labeled Nbl cells. Importantly, the
vasculature of embryo and Nbl cells can be observed
concurrently to evaluate a process of the formation of
metastasis including the cell extravasation towards the distal
CAM (Figures 2B.3, B.4). Moreover, UKF-NB-4 tumors
administered with Elli and CDDP displayed a marked
reduction of the size of the primary tumor in the ex ovo CAM
assay. As shown in Figure 3, after 24 h of exposure to CDDP or
Elli, the UKF-NB-4 microtumors disappeared completely or
mostly, and no evidence of Nbl cells intravasation and
extravasation was found. This highlights the reliability of ex
ovo CAM assay for in vivo screening of compounds with
expected anticancer activity.
In Ovo Chorioallantoic Membrane
Assay Determining the Effect of
Cisplatin and Ellipticine
To study the efficiency of CDDP and Elli to inhibit primary Nbl
tumor growth, intravasation, and extravasation in the organs, we
adapted the in ovo CAM assay protocol previously published by
Crespo et al. (18). Importantly, by using this approach, within 7
days from induction, we achieved 100% (20/20) embryo survival,
and all of them had successfully developed Nbl tumors on CAM
(Figures 4A, A1). Upon termination, tumor growth was assessed
through weight measurements, confirming significant (p < 0.001)
inhibitory cytostatic activity of CDDP (approx. two-fold decline
of primary tumor weight) and Elli (approx. 3.5-fold decline of
primary tumor weight) after 24 h (Figures 4B, C). By further
immunolabeling of CD44, a formed primary tumor in CAM can
be simply visualized, and its margin can be demarcated as shown
in Figure 4D. It was found that the Nbl cells grow from the
primary tumor site to the neighboring CAM, thus disrupting the
upper epithelium of CAM. In addition, Figure 4D clearly shows
intravasated cells in distal CAM.
Another advantageous feature of CAM is that it allows us
simple quantitation of intravasated/extravasated cells through
qPCR with universal human Alu primers that only amplify the
human sequences, while avoiding the amplification of DNA of
host organism. By this approach, we further investigated the
amounts of Nbl cells forming a metastatic spread to different
organs (the liver, lung, brain, and distal CAM). As shown in
Figures 5A, B, in in ovo CAM assay, both studied compoundsSeptember 2021 | Volume 11 | Article 707366
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activity against extravasation to all investigated organs
including distal CAM. Noteworthy, such results are most likely
caused by a high cytostatic activity of relatively high
concentrations (but not high enough to kill the host organism)
of both compounds, resulting in a rapid and efficient arrest of cell
growth and induction of cell death rather than caused by their
antimetastatic activity. Taken together, the obtained data clearly
show that CAM assay could be a helpful and highly efficient inFrontiers in Oncology | www.frontiersin.org 5vivo approach for high-throughput screening of libraries of
compounds with expected anticancer activities.DISCUSSION
This study aimed to highlight the importance of CAM assay for
evaluation of new treatment options relevant for high-risk Nbl.
Nevertheless, it must be noted that the presented methodologiesA
B
FIGURE 2 | (A) Ex ovo-cultivated chicken embryos exhibit physiological development over time. (A.1) Successful transfer of embryo having an intact egg yolk
(on embryonic development day 3), and (A.2–A.4) live embryo on embryonic development from day 3 to 10. (A.4) In vitro-cultured neuroblastoma (Nbl) cells were
transferred on the chick chorioallantoic membrane (CAM) at day 10, and the sites of xenografting were marked on the cover of the Petri dish. (A.5) Harvesting of Nbl
tumors from CAM at day 14. (A.6) The CAM fixation for microscopy. (B) Confocal laser scanning microscopy (CLSM) validation of successful establishment of UKF-
NB-4 xenografts on CAM. (B.1, B.2) Fluorescence angiography showing Nbl microtumors (green, labeled with CellTracker) surrounded by extensive amount of blood
vessels [red, labeled with rhodamine Lens culinaris agglutinin (LCA)]. (B.3, B.4) Invasive vasculotropic Nbl cells that escaped from primary tumor site and
extravasated at the distal CAM. Scale bars, 200 mm.September 2021 | Volume 11 | Article 707366
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one major adjustment: optimization of cancer cell amounts to
develop CAM tumors. The advantages and limitations of the
CAM assay as a versatile in vivo model have been well-described
with a particular emphasis on research in the field of
angiogenesis and carcinogenesis (21, 22). In terms of drug
testing, the majority of available studies utilize CAM assay to
study antiangiogenic or angiogenic potential of examined
compounds/materials and their consequent effect on the
development of embryo (23, 24). However, few available
studies have focused on the use of CAM assay to assess
invasiveness and metastatic potential of Nbl cells (25–27), and
none of them employed CAM assay to investigate the anticancer
compounds. The ex ovo variant of the classical in ovo CAM assay
offers several unique advantages for drug testing. However, it has
been reported by several authors that the ex ovo CAM assay is
associated with worse survival rates (17, 28). This is in line with
our previous experiments during which the survival of embryos in
ex ovo CAM assay is between 50% and 70%. The main advantage
of the ex ovo CAM procedure is facile visualization of the growing
embryo and access to a larger area of the CAM to study size of
tumors and migration of cells into the vessels (8). Besides, in ovoFrontiers in Oncology | www.frontiersin.org 6CAM assay allows easy monitoring of tumor extravasation and
intravasation into the microvasculature and consequent formation
of metastases in organs evaluated by qPCR. Therefore, we provide
the first condensed pipeline demonstrating applicability of CAM
assay (in ovo and ex ovo) as a facile and efficient tool to study the
activity of candidate molecules for anticancer therapy in vivo
without need of rodent facility and associated ethical approvals
and concerns. Besides, the CAM is not innervated so that
experiments are not associated with pain perception by the
embryo, and there is no need for ethical approval for animal
experimentation. Current laws regulating animal experimentation
in the European Union and Switzerland allow experimentation
with chick embryos without authorization from animal
experimentation committees, on the grounds that experiments
begin and end before hatching (until day 17) (29, 30). This could
be of utmost interest for screening purposes as well as for those
experiments not depending on animal facility.
Among the main causes of deaths of children suffering from
Nbl are metastasis and tumor resistance to conventional
treatment (31). A substantial progress of understanding of Nbl
biology has been made in the past decades. This resulted in a
number of clinical trials that have been undertaken to find newA
B
FIGURE 3 | Examination the inhibitory effects of (A) cisplatin (CDDP) and (B) ellipticine (Elli) on neuroblastoma (Nbl) tumor development by ex ovo chick
chorioallantoic membrane (CAM) assay. Confocal laser scanning microscopy (CLSM) micrographs of UKF-NB-4 tumor treated with CDDP and Elli for 24 h (each
photo corresponds to an independent tumor). Viable Nbl cells are green (labeled with CellTracker), and angiogenic vessels are red [labeled with rhodamine Lens
culinaris agglutinin (LCA)]. Scale bar, 200 mm.September 2021 | Volume 11 | Article 707366
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During the metastatic progression, Nbl cells must proceed
through a complex process, which includes invasion,
intravasation, extravasation, and colonization of the target
organs (34). In the presented study, we have shown that by
combining both in ovo and ex ovo approaches, CAM assay can be
employed to comprehensively study these processes in vivo
either when administered with cytostatic drug or non-treated.
Indeed, our results point to the remarkable efficacy of CDDP,
which is a backbone of a first-line therapy of a broad spectrum of
malignant diseases including metastatic ones (35). We also
confirmed the interesting anticancer activity of Elli, which is a
frequently investigated candidate compound suffering from low
bioavailability and a plethora of side effects (36). Importantly, ElliFrontiers in Oncology | www.frontiersin.org 7is a perfect example of an imperfect lead compound that could be
employed for development of novel derivatives with improved
pharmacokinetic and toxicological activities. These can be
investigated in CAM assay in a high-throughput regime. We
are fully aware that screening of drugs using CAM assay does not
have the potential to fully avoid the use of rodent experimental
models. However, we anticipate that inclusion of CAM assay to
the experimental pipelines of large-scale in vivo testing could
result in a faster and cheaper revelation of compounds with a real
therapeutic potential.
It can be concluded that we show that the applicability of
CAM assay can be simply extended from its primary purpose to
study carcinogenesis and angiogenesis to the field of screening of




FIGURE 4 | Determination of efficiency of treatment [cisplatin (CDDP) and ellipticine (Elli)] to inhibit growth of neuroblastoma (Nbl) xenograft. (A) In ovo chick
chorioallantoic membrane (CAM) assay photograph showing representative CAM with the Nbl tumor formed at the seventh day after xenografting. (B) Photographs
and (C) tumor weights after excision from the CAM (upon experiment termination on the 17th day). (D) Immunohistochemical visualization of CD44 expression in Nbl
cells forming primary tumor and outgrowing from primary tumor by disrupting the CAM upper epithelium (black demarcation). Intravasated Nbl cells in the distal CAM
are shown by arrows. Data show mean ± SEM from three (n = 3) independent experiments. *p < 0.001. Scale bar, 200 mm.September 2021 | Volume 11 | Article 707366
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effect of tested compound on the growth of primary tumor, and
subsequent intravasation and extravasation of cancer cells to the
distal organs can be gathered in a simple and cheap way without
any ethical concerns. It must be noted that the applicability of
CAM extends the investigated phenomena and the in vivo nature
of CAM assay also enables a detailed molecular or biochemical
examination of extracted tissues to fully delineate the effect of
drug administration on the exposed organism.DATA AVAILABILITY STATEMENT
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